This article is more than 5 years old. Information may no longer be current.
Recent top stories in ophthalmology
Click Here to Manage Email Alerts
Here are some of the most-read articles on Healio.com/OSN over the past week.
Stress, burnout widespread and underacknowledged among surgeons
Nearly 70% of surgeons suffer from chronic stress, yet stress perception and management are underacknowledged in the surgical community. Read more.
Two-year outcomes show strengths, weaknesses of quarter-DMEK
Two years of follow-up with quarter-Descemet’s membrane endothelial keratoplasty show visual outcomes comparable to those of conventional DMEK surgery and no graft rejection or secondary failure, but the decrease in endothelial cell density calls for further enhancement of the technique. Read more.
Ocular Therapeutix begins Dextenza trial for allergic conjunctivitis
The multicenter, randomized, double-masked, placebo-controlled trial will include 80 subjects and evaluate the safety and efficacy of Dextenza (dexamethasone ophthalmic insert 0.4 mg) compared with a placebo vehicle punctum plug. Read more.
FDA fast tracks potential treatment to prevent proliferative vitreoretinopathy
A phase 3 trial of ADX-2191 is planned for the fourth quarter and will compare recurrence rates of proliferative vitreoretinopathy-related retinal detachment in those treated with ADX-2191 compared with those treated with standard of care following surgical repair of retinal detachment. Read more.
Phase 3b trial to evaluate brolucizumab for wet AMD
The TALON trial is the first treat-to-control study and aims to demonstrate brolucizumab’s superiority in treatment interval duration, while maintaining noninferiority in visual acuity change. Read more.